Canakinumab is a human monoclonal antibody anti-interleukin-1β, it is the only biologic drug approved to treat mevalonate kinase deficiency (MKD). Canakinumab injection can trigger several local cutaneous reactions, but also chronic-relapsing skin infections and other manifestations. We report three cases of unusual cutaneous manifestations in patients treated with canakinumab.
Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab
Conte, Mariasole
;Pastore, Serena;Taddio, Andrea;Tommasini, Alberto
2020-01-01
Abstract
Canakinumab is a human monoclonal antibody anti-interleukin-1β, it is the only biologic drug approved to treat mevalonate kinase deficiency (MKD). Canakinumab injection can trigger several local cutaneous reactions, but also chronic-relapsing skin infections and other manifestations. We report three cases of unusual cutaneous manifestations in patients treated with canakinumab.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2496580-2-4.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright Editore
Dimensione
4.52 MB
Formato
Adobe PDF
|
4.52 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
11368_2970493_print.pdf
accesso aperto
Tipologia:
Bozza finale post-referaggio (post-print)
Licenza:
Digital Rights Management non definito
Dimensione
5.1 MB
Formato
Adobe PDF
|
5.1 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
